CMC Biologics has entered an agreement to supply bulk drug intermediate for CSL Behring’s recently FDA-approved product, AFSTYLA [Antihemophilic Factor (Recombinant), Single Chain], its long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.   CMC Biologics’ facility in Copenhagen, Denmark was inspected by the FDA as part of the approval for the commercial manufacture of AFSTYLA.   “Working together with CSL Behring to achieve th...